更新于：2024-12-16
Amiodarone Hydrochloride
盐酸胺碘酮
更新于：2024-12-16
概要
基本信息
简介胺碘酮，商品名CORDARONE，是一种抗心律失常药物，由Tondeur和Binon化学家于1961年开发。到1980年，在欧洲普遍被开处用于治疗心律失常。在欧洲制药企业切断供应的压力下，1985年12月，尽管没有经过严格的随机临床试验，胺碘酮被FDA批准用于治疗心律失常。胺碘酮被认为是第III类抗心律失常药物，但具有所有四类Vaughan Williams电生理特性。它可以阻塞钠通道和心肌钾通道，有助于减慢传导速度并延长不应期。CORDARONE适用于未对其他抗心律失常药物产生反应的成年人，用于治疗已经记录的危及生命的室颤和不稳定性心动过速。 |
药物类型 小分子化药 |
别名 2-Butyl-3-(3,5-diiodo-4-(2-diethylaminoethoxy)benzoyl)benzofuran、2-Butyl-3-benzofuranyl 4-(2-(diethylamino)ethoxy)-3,5-diiodophenyl ketone、2-n-Butyl-3',5'-diiodo-4'-N-diethylaminoethoxy-3-benzoylbenzofuran + [14] |
作用机制 钾离子通道阻滞剂、钠通道阻滞剂、VDCCs阻滞剂(电压门控性钙通道复合体阻滞剂) |
治疗领域 |
非在研适应症 |
原研机构 |
最高研发阶段批准上市 |
首次获批日期 中国 (1983-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (日本)、孤儿药 (美国) |
登录后查看时间轴
结构
分子式C25H30ClI2NO3 |
InChIKeyITPDYQOUSLNIHG-UHFFFAOYSA-N |
CAS号19774-82-4 |
关联
154
项与 盐酸胺碘酮 相关的临床试验Minocycline Plus Amiodarone Versus Amiodarone Alone for the Prevention of Atrial Fibrillation After Cardiac Surgery (MINA)
BiodEgradable Soaked Amiodarone PaTch Use for the Prevention of Atrial Fibrillation After Cardiac Surgery
Early Amiodarone in Shockable Cardiac Arrest (Early-Amio) Study
100 项与 盐酸胺碘酮 相关的临床结果
登录后查看更多信息
100 项与 盐酸胺碘酮 相关的转化医学
登录后查看更多信息
100 项与 盐酸胺碘酮 相关的专利（医药）
登录后查看更多信息
10,550
项与 盐酸胺碘酮 相关的文献（医药）2025-02-01Journal of Veterinary Cardiology
Efficacy and safety of different antiarrhythmic protocols used for rate control in dogs with secondary atrial fibrillation
Article
作者: Castagna, Prisca ; Bertarello, M ; Valente, C ; Pelle, N G ; Pelle, Nazzareno Giuseppe ; Romito, Giovanni ; Castagna, P ; Guglielmini, Carlo ; Dondi, Francesco ; Fasoli, Sabrina ; Fasoli, S ; Mazzoldi, C ; Romito, G ; Poser, H ; Mazzoldi, Chiara ; Dondi, F ; Valente, Carlotta ; Paradies, Paola ; Paradies, P ; Poser, Helen ; Bertarello, Marina ; Guglielmini, C
INTRODUCTION/OBJECTIVES:
Studies comparing the effects of antiarrhythmic protocols used for rate control in dogs with secondary atrial fibrillation (AF) are currently limited; therefore, this study aimed to report detailed data on the efficacy and therapy-related side-effects (TRSEs) of different antiarrhythmic protocols in dogs with secondary AF.
ANIMALS, MATERIALS, AND METHODS:
Dogs with secondary AF treated with combination therapy with diltiazem and digoxin (CTDilt+Digox), diltiazem monotherapy (MTDilt), digoxin monotherapy (MTDigox), or amiodarone monotherapy (MTAmiod) were retrospectively evaluated. Signalment, clinical, diagnostic, therapeutic, and outcome data were retrieved. Electrocardiographically, antiarrhythmic efficacy was defined by a reduction in the mean heart rate on Holter monitoring ≤125 beats/minutes. Statistical analysis was performed to compare selected data, including the rate of efficacy and TRSEs as well as the median survival time, between dogs treated with different antiarrhythmic protocols.
RESULTS:
Fifty-four dogs were included, with 28 receiving the CTDilt+Digox and 26 receiving monotherapies (MTDigox = 16; MTDilt = 5; MTAmiod = 5). The efficacy rate documented in dogs treated with CTDilt+Digox was significantly higher than that observed in dogs from the composite monotherapy group (i.e., MTDilt+MTDigox+MTAmiod) (P=0.048). The rate of TRSEs documented in dogs treated with CTDilt+Digox was similar to that observed in dogs from the composed monotherapy group (P=0.129). The median survival time documented in dogs treated with CTDilt+Digox was significantly longer than that observed in dogs of the MTDigox group (P=0.01).
DISCUSSION:
In dogs with secondary AF we included, CTDilt+Digox was well tolerated and provided clinically relevant benefits compared to the use of a single antiarrhythmic drug.
LIMITATIONS:
Retrospective design; heterogeneous sample size of categories analyzed; clinicopathological data available for many, but not all, dogs.
CONCLUSIONS:
Our findings support the indication to generally consider CTDilt+Digox as a first-line antiarrhythmic treatment in dogs with secondary AF.
2025-02-01JOURNAL OF PHARMACY PRACTICE
Amiodarone-Induced Anaphylaxis
Review
作者: Tang, Michelle ; Zhong, Qing ; Nunna, Nitya
Background: Amiodarone-induced anaphylaxis is seldom reported. The mechanism of this anaphylaxis is unknown. Methods: A literature search was carried out with keywords “Amiodarone” and “Anaphylaxis” and “polysorbate 80” or “hypotension.” A search using “amiodarone” in the FDA Adverse Event Reporting System (FAERS) from 1969 to 2024 was also conducted. Results: There are a total of 10 cases of amiodarone-induced anaphylaxis in the literature. Six patients were male. Ages ranged from 15 to 86 years old. Nine cases were triggered by intravenous injection (IV) and one by oral administration. Eight patients did not have previous exposure to amiodarone. The trigger times for IV amiodarone were immediate to 90 minutes. All nine cases of IV amiodarone resulted in hypotension (90%), with an immeasurable blood pressure (70%). Presentations included bronchospasm or a skin rash (60%), angioedema (40%), and unconsciousness (20%). Only one patient had a history of allergy to penicillin and sulfonamide. An amiodarone skin test was positive on one patient. Increased blood tryptase (4 cases), positive basophil activation test to amiodarone (2 cases), increased eosinophil count (1 case), and increased serum IgE (1 case) were reported. Amiodarone was terminated in 80% of the patients. Epinephrine, norepinephrine, antihistamine-1, or steroids were used to rescue patients. Four patients were intubated. All patients fully recovered. In the FAERS database, 89 cases of amiodarone-associated anaphylaxis were reported, resulting in 14 deaths. Conclusions: Solvent polysorbate 80, amiodarone, and iodide may contribute to amiodarone-induced anaphylaxis. Prompt treatment is the key to saving patients.
2025-01-01Radiology case reports
One artery to rule them all: A case of single coronary artery arising from the right sinus of Valsalva
Article
作者: Ioakeimidis, Nikolaos S. ; Pepis, Panagiotis ; Valasiadis, Dimitrios ; Ioakeimidis, Nikolaos S ; Mitrousi, Konstantina
A single coronary artery (SCA) is a rare congenital anomaly with an incidence of 0.024 - 0.066% in angiographies and potential implications for adverse events depending on the course of the anomalous artery. We present a unique case of a single coronary artery arising from the right sinus of Valsalva. A 77-year-old female presented to the emergency department with an ongoing 3-hour episode of palpitations and intermittent atypical chest pain over 1 week. Her medical history included hypertension and dyslipidemia. Electrocardiography revealed atrial fibrillation with rapid ventricular response, which was successfully managed with intravenous amiodarone and the diagnostic workup ruled out life threatening thoracic pathology including cardiac ischemia. A CT coronary angiography was performed due to the moderate pretest probability of coronary artery disease. The scan identified a single coronary artery with a common origin of the left main coronary artery (LMCA) and the right coronary artery (RCA), from the right sinus of Valsalva, classified as Lipton Type RII-A which is a benign variant. This case highlights the importance of identifying CAAs, which are often incidental but may have clinical relevance depending on the anatomical course and associated risk factors. Early and accurate diagnosis through advanced imaging techniques is crucial to guide appropriate management and ensure optimal outcomes for the patient.
100 项与 盐酸胺碘酮 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心脏停搏 | 日本 | 2013-05-31 | |
| 心房颤动 | 日本 | 1992-07-03 | |
| 室性心动过速 | 美国 | 1985-12-24 | |
| 心室颤动 | 美国 | 1985-12-24 | |
| 心律失常 | 中国 | 1983-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 心脏衰竭 | 临床2期 | - | 2008-08-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 323 | Amiodarone | 齋積繭蓋襯衊鬱餘壓遞(顧窪選選淵襯艱餘夢遞) = 餘衊襯積夢範網遞鏇餘 艱獵鹽構衊遞齋衊艱衊 (廠繭艱餘鹽憲艱膚鏇廠 ) 更多 | 不佳 | 2024-10-02 | ||
齋積繭蓋襯衊鬱餘壓遞(顧窪選選淵襯艱餘夢遞) = 簾廠願願膚顧網醖範醖 艱獵鹽構衊遞齋衊艱衊 (廠繭艱餘鹽憲艱膚鏇廠 ) 更多 | |||||||
N/A | - | Preoperative amiodarone use | 淵鬱廠壓壓衊構願鹹夢(淵繭製憲構壓艱製壓網) = 壓鏇夢簾夢範獵蓋願壓 壓網餘範簾蓋積簾獵製 (構醖網繭廠齋醖餘鏇選 ) | - | 2024-05-13 | ||
淵鬱廠壓壓衊構願鹹夢(淵繭製憲構壓艱製壓網) = 糧範顧蓋夢鑰鏇餘築繭 壓網餘範簾蓋積簾獵製 (構醖網繭廠齋醖餘鏇選 ) | |||||||
临床4期 | - | 範獵齋糧觸壓製觸鬱艱(築築鑰膚鑰醖衊顧蓋膚): HR = 0.6 (95% CI, 0.4 ~ 0.9), P-Value = 0.014 | 积极 | 2024-02-19 | |||
临床4期 | 3 | (Conventional Amiodarone Dosing Regimen (CDR)) | 願顧齋製鬱選鑰廠糧壓(憲壓齋繭膚淵範範積願) = 蓋觸築齋艱艱顧憲製構 鬱蓋醖獵夢簾積鏇範積 (鑰衊餘醖繭鹹蓋鹽築廠, 鑰鹽壓衊壓襯網顧窪積 ~ 醖鏇網夢窪鑰鹹範選簾) 更多 | - | 2023-11-18 | ||
(Repeated Amiodarone Bolus Dosing Regimen (RBDR)) | 願顧齋製鬱選鑰廠糧壓(憲壓齋繭膚淵範範積願) = 窪艱遞膚選製淵齋廠顧 鬱蓋醖獵夢簾積鏇範積 (鑰衊餘醖繭鹹蓋鹽築廠, 選憲範顧淵壓簾選淵願 ~ 衊齋糧壓夢衊襯餘築廠) 更多 | ||||||
N/A | - | - | Beta-blockers plus amiodarone | 觸憲蓋製鬱範積獵觸齋(範膚顧範衊願憲襯鬱築) = amiodarone was not associated with a significantly reduced risk of ICD discharges 繭憲願遞壓廠製鏇鑰製 (窪衊餘鬱壓鬱願遞壓範 ) 更多 | - | 2023-08-28 | |
N/A | 心房颤动 一线 | - | 願夢醖淵鹹廠窪淵膚築(選鏇鑰製構餘獵壓憲顧): hazard ratio = 2.52 (95% CI, 2.202 ~ 2.883) | 不佳 | 2023-08-25 | ||
Other-AADs | |||||||
N/A | - | 壓繭壓觸顧選鬱壓鬱憲(淵膚觸鹹膚餘鏇顧繭鹹) = She was hypotensive, hypothermic (35.0°C) and bradycardic with a heart rate of 40 beats per minute 積糧獵蓋壓繭網構鏇鏇 (夢願選淵鑰鑰築範齋積 ) 更多 | - | 2023-05-21 | |||
N/A | 1,251 | Previous use of oral amiodarone | 網壓鑰襯餘觸壓憲積夢(獵鏇獵鹽積繭繭觸糧鑰) = 窪願遞鑰鹽夢齋憲積遞 築範糧範範廠選壓廠簾 (觸鬱齋壓鏇獵蓋築壓襯 ) 更多 | 积极 | 2023-05-21 | ||
N/A | - | Amiodarone use | 繭醖構觸夢衊壓齋夢齋(襯選構範鹹膚顧憲衊廠) = 積艱鏇艱膚淵築淵積窪 願艱願艱淵獵簾艱蓋鑰 (餘選糧獵鑰衊廠構齋蓋 ) 更多 | - | 2023-05-21 | ||
No amiodarone use | 繭醖構觸夢衊壓齋夢齋(襯選構範鹹膚顧憲衊廠) = 齋簾積築鏇範選築窪鹽 願艱願艱淵獵簾艱蓋鑰 (餘選糧獵鑰衊廠構齋蓋 ) 更多 | ||||||
N/A | - | - | Amiodarone 400 mg twice daily | 獵鬱鬱選製餘憲糧願醖(憲製窪廠觸構淵鑰淵夢) = progressive dyspnea on exertion and acute hypoxic respiratory failure, worsening fatigue and dyspnea with activities of daily living, patchy interstitial airspace disease, foamy macrophages, recurrence of symptoms requiring supplemental oxygen 鏇襯鬱艱範範蓋積壓窪 (積衊壓構廠壓鑰鹹範簾 ) | - | 2023-05-21 | |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用